ABSTRACT
OBJECTIVE: The French Society of Anesthesiology and Intensive Care Medicine [Société Française d'Anesthésie et de Réanimation (SFAR)] aimed at providing guidelines for the implementation of perioperative optimization programs. DESIGN: A consensus committee of 29 experts from the SFAR was convened. A formal conflict-of-interest policy was developed at the outset of the process and enforced throughout. The entire guidelines process was conducted independently of any industry funding. The authors were advised to follow the principles of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to guide assessment of quality of evidence. METHODS: Four fields were defined: 1) Generalities on perioperative optimization programs; 2) Preoperative measures; 3) Intraoperative measures and; 4) Postoperative measures. For each field, the objective of the recommendations was to answer a number of questions formulated according to the PICO model (population, intervention, comparison, and outcomes). Based on these questions, an extensive bibliographic search was carried out using predefined keywords according to PRISMA guidelines and analyzed using the GRADE® methodology. The recommendations were formulated according to the GRADE® methodology and then voted on by all the experts according to the GRADE grid method. As the GRADE® methodology could have been fully applied for the vast majority of questions, the recommendations were formulated using a "formalized expert recommendations" format. RESULTS: The experts' work on synthesis and application of the GRADE® method resulted in 30 recommendations. Among the formalized recommendations, 19 were found to have a high level of evidence (GRADE 1±) and ten a low level of evidence (GRADE 2±). For one recommendation, the GRADE methodology could not be fully applied, resulting in an expert opinion. Two questions did not find any response in the literature. After two rounds of rating and several amendments, strong agreement was reached for all the recommendations. CONCLUSIONS: Strong agreement among the experts was obtained to provide 30 recommendations for the elaboration and/or implementation of perioperative optimization programs in the highest number of surgical fields.
Subject(s)
Anesthesiology , Critical Care , Adult , HumansABSTRACT
OBJECTIVES: Postoperative atrial fibrillation (POAF) is a major complication after cardiac surgery, and an early postoperative introduction of beta-blockers is recommended to reduce its incidence. Landiolol, a new intravenous short-acting beta-1 blocker, could present a useful and safe macrohemodynamic profile after cardiac surgery. Detailed metabolic and hemodynamic effects of landiolol on cardiac performance, however, remain poorly documented. The authors aimed to investigate the dose-dependent hemodynamic and metabolic effects of landiolol in that specific setting. DESIGN: A prospective, randomized, double-blind study versus placebo. SETTING: A tertiary university hospital. PARTICIPANTS: Adult patients scheduled for elective cardiac surgery with cardiopulmonary bypass. INTERVENTIONS: Incremental doses of intravenous landiolol (0.5, 1, 2, 5, and 10 µg/kg/min) were given within the 2 hours after arrival in the intensive care unit. Macrocirculatory parameters and cardiac performances were derived from transpulmonary thermodilution and transthoracic echocardiography. Metabolic data were obtained from arterial blood tests. MEASUREMENTS AND MAIN RESULTS: From January to November 2019, 58 patients were analyzed and divided into a landiolol group (n = 30) and a control group (n = 28). Heart rate significantly decreased in the landiolol group (p < 0.01), whereas mean arterial pressure and stroke volume remained unchanged. No significant modification was found in both left and right systolic and diastolic performances. Metabolic variables were similar in both groups. New-onset POAF occurred in 9 (32%) versus 5 (17%) patients in the control and landiolol groups, respectively (p = 0.28). CONCLUSIONS: Infusion of landiolol in the range of 0.5-to-10 µg/kg/min during the early postoperative period presents a good macrohemodynamic safety profile in cardiac surgical patients and could be useful to prevent POAF.
Subject(s)
Atrial Fibrillation , Cardiac Surgical Procedures , Adrenergic beta-Antagonists , Atrial Fibrillation/drug therapy , Atrial Fibrillation/etiology , Atrial Fibrillation/prevention & control , Cardiac Surgical Procedures/adverse effects , Humans , Morpholines , Postoperative Complications/drug therapy , Postoperative Complications/etiology , Postoperative Complications/prevention & control , Prospective Studies , Urea/analogs & derivativesSubject(s)
Adrenergic beta-Antagonists/therapeutic use , Anti-Arrhythmia Agents/therapeutic use , Atrial Fibrillation/prevention & control , Cardiac Surgical Procedures , Cardiopulmonary Bypass , Heart Rate/drug effects , Microcirculation/drug effects , Morpholines/therapeutic use , Urea/analogs & derivatives , Adrenergic beta-Antagonists/adverse effects , Anti-Arrhythmia Agents/adverse effects , Atrial Fibrillation/etiology , Atrial Fibrillation/physiopathology , Cardiac Surgical Procedures/adverse effects , Cardiopulmonary Bypass/adverse effects , Double-Blind Method , Humans , Morpholines/adverse effects , Prospective Studies , Time Factors , Treatment Outcome , Urea/adverse effects , Urea/therapeutic useSubject(s)
Anesthesia, General , Carotid Artery Thrombosis/therapy , Conscious Sedation , Infarction, Middle Cerebral Artery/therapy , Mechanical Thrombolysis , Perioperative Medicine/trends , Anesthesia, General/adverse effects , Anesthesia, General/methods , Brain Damage, Chronic/etiology , Brain Damage, Chronic/prevention & control , Carotid Artery Thrombosis/complications , Conscious Sedation/adverse effects , Conscious Sedation/methods , Emergency Medical Services/methods , Equivalence Trials as Topic , Humans , Infarction, Middle Cerebral Artery/complications , Mechanical Thrombolysis/adverse effects , Mechanical Thrombolysis/methods , Meta-Analysis as Topic , Perioperative Medicine/methods , Randomized Controlled Trials as TopicSubject(s)
Airway Extubation , Respiration, Artificial , Humans , Intensive Care Units , Respiration , Ventilator WeaningSubject(s)
Aortic Valve Stenosis/surgery , Transcatheter Aortic Valve Replacement , Age Factors , Aortic Valve/surgery , Humans , Postoperative Complications , Randomized Controlled Trials as Topic , Risk Assessment , Stroke/etiology , Transcatheter Aortic Valve Replacement/adverse effects , Transcatheter Aortic Valve Replacement/methods , Transcatheter Aortic Valve Replacement/mortalityABSTRACT
Landiolol is an intravenous ultra-short acting beta-blocker which has been used in Japan for many years to prevent and/or to treat post-operative atrial fibrillation following cardiac surgery. The drug is now available in Europe. This article is a systematic review of literature regarding the use of landiolol in that specific surgical setting.